Recent Advances in Pyrazole-based Protein Kinase Inhibitors as Emerging Therapeutic Targets

被引:0
|
作者
Cetin, Adnan [1 ]
机构
[1] Van Yuzuncu Yil Univ, Fac Educ, Dept Chem, TR-65080 Van, Turkiye
关键词
Cancer; drug discovery; pharmacology; spectroscopy; pyrazole-based protein kinase inhibitors; therapeutic targets; PATENT CITATIONS; SERINE-PROTEASE; POTENT; AGENTS; EGFR;
D O I
10.2174/0113862073252211231024182817
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background Pyrazole-scaffold protein kinase inhibitors (PKIs) have emerged as promising therapeutic agents for the treatment of various diseases, such as cancer, inflammatory disorders, and neurological diseases. This review article provides an overview of the pharmacological properties of pyrazole-scaffold PKIs, including their mechanism of action, selectivity, potency, and toxicity. The article also summarizes the recent developments in the design and synthesis of pyrazole-scaffold PKIs, highlighting the structural features and modifications that contribute to their pharmacological activity. In addition, the article discusses the preclinical and clinical studies of pyrazole-scaffold PKIs, including their efficacy, safety, and pharmacokinetic properties.Methods A comprehensive search has been conducted on several online patent databases, including the United States Patent and Trademark Office (USPTO), the European Patent Office (EPO), and the World Intellectual Property Organization (WIPO). The search was conducted using pyrazole as the keyword. The search was limited to patents filed between 2015 and 2022. Patents were included if they involved articles in the fields of protein kinase inhibitors, and included literature on some pyrazoles and their pharmacological activities.Results Data were extracted from each included patent on the following variables: patent title, patent number, inventors, assignee, filing date, publication date, patent type, and field of invention. Data were extracted from each patent using a standardized form to ensure consistency and accuracy.Conclusion The design and pharmacological evaluation of organic compounds containing pyrazole structure as biologically active substances have been done, and the key structures from the pharmacological data obtained as protein kinase inhibitors have been addressed in detail. The review concludes with a discussion on the current challenges and future directions for the development of pyrazole-scaffold PKIs as therapeutic agents. Overall, this review article provides a comprehensive summary of the pharmacological properties of pyrazole-scaffold PKIs, which will be of interest to researchers and clinicians in the field of drug discovery and development.
引用
收藏
页码:2791 / 2804
页数:14
相关论文
共 50 条
  • [21] Evaluation of Substituted Pyrazole-Based Kinase Inhibitors in One Decade (2011-2020): Current Status and Future Prospects
    El-Gamal, Mohammed I.
    Zaraei, Seyed-Omar
    Madkour, Moustafa M.
    Anbar, Hanan S.
    MOLECULES, 2022, 27 (01):
  • [22] Parallel synthesis of potent, pyrazole-based inhibitors of Helicobacter pylori dihydroorotate dehydrogenase
    Haque, TS
    Tadesse, S
    Marcinkeviciene, J
    Rogers, MJ
    Sizemore, C
    Kopcho, LM
    Amsler, K
    Ecret, LD
    Zhan, DL
    Hobbs, F
    Slee, A
    Trainor, GL
    Stern, AM
    Copeland, RA
    Combs, AP
    JOURNAL OF MEDICINAL CHEMISTRY, 2002, 45 (21) : 4669 - 4678
  • [23] Glioblastoma: Current Status, Emerging Targets, and Recent Advances
    Thakur, Amandeep
    Faujdar, Chetna
    Sharma, Ram
    Sharma, Sachin
    Malik, Basant
    Nepali, Kunal
    Liou, Jing Ping
    JOURNAL OF MEDICINAL CHEMISTRY, 2022, 65 (13) : 8596 - 8685
  • [24] Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?
    Bortolato, Andrea
    Cozza, Giorgio
    Moro, Stefano
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (07) : 798 - 806
  • [25] Pyrazole-Based Lactate Dehydrogenase Inhibitors with Optimized Cell Activity and Pharmacokinetic Properties
    Rai, Ganesha
    Urban, Daniel J.
    Mott, Bryan T.
    Hu, Xin
    Yang, Shyh-Ming
    Benavides, Gloria A.
    Johnson, Michelle S.
    Squadrito, Giuseppe L.
    Brimacombe, Kyle R.
    Lee, Tobie D.
    Cheff, Dorian M.
    Zhu, Hu
    Henderson, Mark J.
    Pohida, Katherine
    Sulikowski, Gary A.
    Dranow, David M.
    Kabir, Md
    Shah, Pranav
    Padilha, Elias
    Tao, Dingyin
    Fang, Yuhong
    Christov, Plamen P.
    Kim, Kwangho
    Jana, Somnath
    Muttil, Pavan
    Anderson, Tamara
    Kunda, Nitesh K.
    Hathaway, Helen J.
    Kusewitt, Donna F.
    Oshima, Nobu
    Cherukuri, Murali
    Davies, Douglas R.
    Norenberg, Jeffrey P.
    Sklar, Larry A.
    Moore, William J.
    Dang, Chi, V
    Stott, Gordon M.
    Neckers, Leonard
    Flint, Andrew J.
    Darley-Usmar, Victor M.
    Simeonov, Anton
    Waterson, Alex G.
    Jadhav, Ajit
    Hall, Matthew D.
    Maloney, David J.
    JOURNAL OF MEDICINAL CHEMISTRY, 2020, 63 (19) : 10984 - 11011
  • [26] Development of non-peptide pyrazole-based proteasome inhibitors as anticancer agents
    Miller, Zachary
    Lee, Domin
    Lee, Na-Ra
    Ao, Lin
    Zhan, Chang-Guo
    Lee, Wooin
    Kim, Dong-Eun
    Kim, Kyung-Bo
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2014, 248
  • [27] Design and Synthesis of Novel Pyrazole-based Lp-PLA2 Inhibitors
    Wang Yi
    Xu Weiren
    Shao Hua
    Xie Yafei
    Wang Jianwu
    CHINESE JOURNAL OF CHEMISTRY, 2011, 29 (10) : 2039 - 2048
  • [28] Recent advances in the development of sphingosine kinase inhibitors
    Pitman, Melissa R.
    Costabile, Maurizio
    Pitson, Stuart M.
    CELLULAR SIGNALLING, 2016, 28 (09) : 1349 - 1363
  • [29] Recent Advances in the Field of Kinases and Kinase Inhibitors
    Huang, Zunnan
    Lee, Mee-Hyun
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (29) : 4207 - 4208
  • [30] Recent advances in the discovery of Src kinase inhibitors
    Parang, K
    Sun, GQ
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2005, 15 (09) : 1183 - 1207